Public Database for HIV Drug Resistance in southern Africa. Nature, 464(7289): 673 (2010).

Publication Latest Publications

Title: Public Database for HIV Drug Resistance in southern Africa
Authors: de Oliveira T, Shafer WR, Seebregts C, for SATuRN.
Journal: Nature,464(7289):673 (2010)

Journal Impact Factor (I.F.): 34.48
Number of citations (Google Scholar): 27

Abstract

The Opinion article by S. Karim and Q. Karim laments the lack of an effective conduit between South Africa's AIDS research and its prevention and treatment policies and programmes (Nature 463, 733?734; 2010). We would like to draw attention to an HIV-1 drug-resistance database, a scientific resource for regional and global HIV research that will enhance surveillance programmes in southern Africa.

The database was established by investigators from the Southern African Treatment and Resistance Network (SATuRN), in collaboration with researchers from the United States and Europe. SATuRN will provide national departments of health with highquality, up-to-date information to guide delivery of antiretroviral therapy, helping to ensure the long-term success of antiretroviral treatment programmes. As part of this network, we have installed a South African mirror of the Stanford HIV Drug Resistance Database (HIVDB). This mirror (www.bioafrica.net/saturn) will be continuously updated and released to local investigators in a curated and readily analysable form, in the context of more than 120,000 sequences already in the Stanford HIVDB. Neighbouring countries that share subtype C as the predominant virus (the strain fuelling southern Africa'sAIDS epidemic) are also providing data.

The mirror will ensure that subtype-C sequences are analysed according to standard state-of-the-art technologies developed by Stanford HIVDB. It will help patient management, allowing quick identification of resistant strains and systematic tracking both of resistance patterns and of prevalence and distribution of resistance mutations within different population groups. It will inform decisions about new drugs, diagnostics and treatment strategies in southern Africa.

Already, the data show that resistance in newly infected individuals is still very low (under 5%), as is the accumulation of thymidine-analogue mutations that can limit the effectiveness of second-line antiretroviral therapy. Investigators, clinicians and laboratories wishing to take part in the collaboration should contact the authors.

Download: Full text paper

Citation: de Oliveira T, Shafer WR, Seebregts C, for SATuRN. Public Database for HIV Drug Resistance in southern Africa Nature,464(7289):673 (2010).

Printed and Online Media Coverage

Impilo Dialogues - DoH newsletter

Public database for HIV drug resistance in southern Africa

Impilo Dialogues - DoH newsletter - 2011-06-25

PRETORIA - We would like to draw attention to an HIV-1 drug resistance database, a scientific resource for regional and global HIV research that will enhance surveillance programmes in southern Africa.The database was established by investigators from the Southern African Treatment and Resistance Network (SATuRN), in collaboration with researchers from the United States & Europe. SAT- uRN will provide national de- partments of health with high quality, up-to-date information to guide delivery of antiretroviral ther- apy, helping to ensure the long -term success of antiretroviral treatment programmes.


UKZN

Highly Specialized Team to Tackle HIV Drug Resistance Problem in Southern Africa

UKZN - 2012-02-22

DURBAN, SOUTH AFRICA, 24-26 FEB 2012 - A small, highly specialized multidisciplinary team of doctors and statisticians from South Africa, Botswana, the USA and the UK will meet in Durban this weekend with the express purpose of pooling their resources, knowledge and expertise in an attempt to improve understanding the problem of HIV drug resistance in southern Africa.


LabMedica

Collaboration to Undertake HIV Resistance Testing in Africa

LabMedica - 2012-08-06

Sequencing-based diagnostics for human immunodeficiency virus (HIV)-infected individuals will be carried out in Africa in order to determine resistance to antiretroviral drugs.


CAPRISA

Creating access to HIV/TB drug resistance testing

CAPRISA - 2012-08-01

During July, the acclaimed researcher, Dr Tulio de Oliveira from the Southern African Treatment Research Network (SATuRN), was invited to CAPRISA to visit CAPRISA's eThekwini Clinical Research Site. He also presented latest developments on affordable HIV and TB drug resistance testing and open access, public, drug resistance databases to CAPRISA's management team, followed by discussions on possible opportunities for collaboration.


International Innovation

The Network Marker

International Innovation - 2013-04-22

Drug resistance poses significant potential problems in the fight against HIV and TB, but little is known about how best to tackle it. Dr Tulio de Oliveira heads a network that aims to fill this knowledge gap.


Africa Centre & UKZN DVC

16.5 million rand to convert cutting-edge HIV research in rural South Africa into national policy

Africa Centre & UKZN DVC - 2013-10-31

Professor Salim Abdool Karim and Health Minister, Dr Aaron Motsoaledi, awarded a R16.5 million grant to fight HIV drug resistance and transmission in rural KwaZulu-Natal.



High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients
Journal: Clinical Infectious Diseases (2017)

Virological Outcomes of Second-line Protease Inhibitor?Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis
Journal: Clinical Infectious Diseases (2017)

CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients
Journal: Current HIV Research (2017)
All publications...


Page design updated by Tulio de Oliveira, 2013